Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152437 | 0.89 | KDM4E (0.56) | KDM4EPKMGPR119GAAUSP30 | |
| SCHEMBL3249170 | 0.85 | KDM4E (0.61) | KDM4EPKMGPR119STSCSF1R | |
| SCHEMBL313831 | 0.85 | ALDH1A1 (0.55) | GPR119 | |
| SCHEMBL5190669 | 0.83 | HPGD (0.51) | KDM4EPKMGPR119 | |
| SCHEMBL4209884 | 0.83 | KDM4E (0.65) | KDM4EPKMGPR119USP30STS | |
| SCHEMBL3362056 | 0.81 | KDM4E (0.57) | KDM4EPKMGPR119GAASTS | |
| SCHEMBL14681031 | 0.81 | KDM4E (0.57) | KDM4EPKMGPR119STSTGFBR1 | |
| Benzene SCHEMBL3362058 | 0.81 | KDM4E (0.55) | KDM4EPKMGPR119STSTGFBR1 | |
| SCHEMBL6148210 | 0.80 | KDM4E (0.71) | KDM4EPKMGPR119GAASTS | |
| SCHEMBL5190671 | 0.79 | KDM4E (0.52) | KDM4EPKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | KDM4E 470/4885PKM 3864/4885GPR119 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.